8-K: MariMed Reports Record Q3 Revenue, Eyes Growth

MariMed Inc. announced record third-quarter revenue of $44.2 million, driven by sequential growth in wholesale and retail, alongside improved operational cash flow.

Summary

• MariMed Inc. reported record third-quarter revenue of $44.2 million for the period ending September 30, 2026, an increase of 5.5% sequentially and 8.5% year-over-year.
• The company achieved a Non-GAAP Adjusted EBITDA of $4.7 million, an 18% sequential increase, though Non-GAAP Adjusted EBITDA margin decreased to 11% from 13% year-over-year.
• GAAP Net loss for the quarter was $3.5 million, an improvement from $2.9 million in the prior year's quarter, but the nine-month net loss widened to $10.8 million from $9.8 million.
• Wholesale revenue grew 5.2% sequentially and 8.1% year-over-year, while retail revenue increased 5.4% sequentially and 8.4% year-over-year.
• The company ended the quarter with $10.4 million in cash and cash equivalents, its strongest position in two years, reflecting positive cash flow from operations.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, indicating sequential growth and historical revenue highs, but tempered by declining year-over-year margins and continued net losses.

Positives

• Achieved record quarterly revenue of $44.2 million, up 8.5% year-over-year.
• Sequential revenue growth of 5.5% in Q3 2026.
• Non-GAAP Adjusted EBITDA increased 18% sequentially to $4.7 million.
• Generated positive cash flow from operations, reaching the strongest cash position in two years with $10.4 million in cash and cash equivalents.
• Wholesale revenue increased 8.1% year-over-year.
• Retail revenue increased 8.4% year-over-year.
• Transactions across the Thrive retail network increased 7% year-over-year.
• Thrive Perks Loyalty Program membership increased 31% year-to-date.

Negatives

• GAAP Net loss for the third quarter was $3.5 million, compared to $2.9 million in the prior year.
• Non-GAAP Adjusted EBITDA margin declined to 11% from 13% year-over-year.
• GAAP Gross margin decreased to 38.8% from 40.1% year-over-year.
• Nine-month GAAP Net loss increased to $10.8 million from $9.8 million in the prior year.
• Continued wholesale price compression impacted margins.

Risks

• Reductions in customer spending.
• Ability to recruit and retain key personnel.
• Disruptions from the integration efforts of acquired companies.
• Changes in demand for the Company's services and products.
• Changes in the law and its enforcement.
• Changes in the economic environment.
• Continued wholesale price compression.

Future Outlook

MariMed plans to leverage its brands, cash position, and production capacity to continue growing market share, open new accounts, and invest in the business in the fourth quarter and into next year. The company will also monitor developments regarding federal cannabis reform, 280E tax relief, and banking reform as potential industry catalysts.

Management Comments

• "I'm pleased to report that the momentum we built earlier this year extended through the third quarter. Wholesale and retail revenue both grew sequentially and year over year, and total revenue reached another record for MariMed."
• "Adjusted EBITDA improved from the prior quarter, and we again generated positive cash flow from operations, ending the quarter in our strongest position in more than two years."
• "Consumers continue to respond to our brands, our stores are growing the number of customers we serve and retaining them, and our operating model lets us adapt quickly as markets and opportunities evolve."
• "Our focus in the fourth quarter and into next year will be leveraging our brands, cash position, production capacity, and the momentum we've built so far this year to continue growing market share, open new accounts, and invest in the business."

Industry Context

StockSavvy.ai notes that MariMed's performance, particularly its record revenue and sequential growth, aligns with a general trend of recovery and expansion in select multi-state cannabis markets, despite ongoing challenges like wholesale price compression and regulatory uncertainties.

Comparison to Industry Standards

• The report indicates that MariMed's wholesale price compression is an industry-wide challenge, affecting margins across the sector.
• Bettys Eddies fruit chews maintaining the #1-selling edible brand position in core markets suggests strong brand performance relative to competitors within those specific categories.
• The company's ability to adapt its operating model and pricing strategies to deepen customer engagement and encourage repeat visits is a key differentiator in a competitive retail landscape.

Stakeholder Impact

• Shareholders may see potential for increased value through continued market share growth and operational improvements, though current net losses and margin pressures present risks.
• Employees may benefit from the company's focus on operational efficiency and growth, potentially leading to increased stability and opportunities.
• Customers are likely to continue experiencing strong brand offerings and customer engagement initiatives at retail locations.
• Suppliers may see increased demand due to revenue growth, but could also be impacted by ongoing wholesale price compression.

Next Steps

• Continue growing market share.
• Open new accounts.
• Invest in the business.
• Monitor developments regarding federal cannabis reform, 280E tax relief, and banking reform.

Key Dates

Recommendation

The report shows record revenue and sequential growth, which is positive. However, the continued net losses, declining year-over-year margins, and industry-wide price compression warrant a cautious approach. While operational improvements are evident, the path to consistent profitability and the impact of external factors like regulatory reform remain key uncertainties, suggesting a 'hold' position until clearer trends emerge.

Keywords

cannabis operator, revenue, earnings, EBITDA, gross margin, retail, wholesale, financial results